Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Humans
Carcinoma, Renal Cell
/ mortality
Female
Male
Middle Aged
Kidney Neoplasms
/ mortality
Adult
Aged
Young Adult
Adolescent
Sex Factors
Immune Checkpoint Inhibitors
/ therapeutic use
Prognosis
Immunotherapy
/ methods
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Survival Rate
Aged, 80 and over
ARON-1 study
Gender differences
Immune-based combinations
Immunotherapy
NCT05287464
Renal cell carcinoma
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
01
04
2024
accepted:
29
04
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
Sections du résumé
BACKGROUND
BACKGROUND
There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking.
METHOD
METHODS
This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy.
RESULTS
RESULTS
A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008).
CONCLUSIONS
CONCLUSIONS
Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
Identifiants
pubmed: 38832989
doi: 10.1007/s00262-024-03719-0
pii: 10.1007/s00262-024-03719-0
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
142Informations de copyright
© 2024. The Author(s).
Références
Hirsch L, Flippot R, Escudier B, Albiges L (2020) Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs 80(12):1169–1181. https://doi.org/10.1007/s40265-020-01327-7 . (PMID: 32601914)
doi: 10.1007/s40265-020-01327-7
pubmed: 32601914
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Meli- char B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115
doi: 10.1056/NEJMoa1816047
pubmed: 30779531
pmcid: 6716603
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189):2404–2415
doi: 10.1016/S0140-6736(19)30723-8
pubmed: 31079938
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127
doi: 10.1056/NEJMoa1816714
pubmed: 30779529
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300
doi: 10.1056/NEJMoa2035716
pubmed: 33616314
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841
doi: 10.1056/NEJMoa2026982
pubmed: 33657295
pmcid: 8436591
Díaz-Montero CM, Rini BI, Finke JH (2020) The immunology of renal cell carcinoma. Nat Rev Nephrol 16(12):721–735. https://doi.org/10.1038/s41581-020-0316-3 . (Epub 2020 Jul 30 PMID: 32733094)
doi: 10.1038/s41581-020-0316-3
pubmed: 32733094
Wang PF, Song HF, Zhang Q, Yan CX (2020) Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy. Eur J Cancer 126:136–138. https://doi.org/10.1016/j.ejca.2019.12.008 . (Epub 2020 Jan 9 PMID: 31927214)
doi: 10.1016/j.ejca.2019.12.008
pubmed: 31927214
Oertelt-Prigione S (2012) The influence of sex and gender on the immune response. Autoimmun Rev 11(6–7):A479–A485. https://doi.org/10.1016/j.autrev.2011.11.022 . (Epub 2011 Dec 3 PMID: 22155201)
doi: 10.1016/j.autrev.2011.11.022
pubmed: 22155201
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G et al (2018) Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 19(6):737–746. https://doi.org/10.1016/S1470-2045(18)30261-4 . (Epub 2018 May 16 PMID: 29778737)
doi: 10.1016/S1470-2045(18)30261-4
pubmed: 29778737
Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O et al (2019) Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol 5(4):529–536. https://doi.org/10.1001/jamaoncol.2018.5904
doi: 10.1001/jamaoncol.2018.5904
pubmed: 30605213
pmcid: 6459215
Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L et al (2022) The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol 170:103596. https://doi.org/10.1016/j.critrevonc.2022.103596 . (Epub 2022 Jan 12 PMID: 35031442)
doi: 10.1016/j.critrevonc.2022.103596
pubmed: 35031442
Graham J, Abdel-Rahman O, Choueiri TK, Heng DYC (2018) International mRCC Database Consortium. Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 19:737–46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. Eur Urol. 74(6):e139-e140. https://doi.org/10.1016/j.eururo.2018.07.004
Yanagisawa T, Kawada T, Quhal F, Bekku K, Laukhtina E, Rajwa P et al (2023) Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol 41(7):1763–1774. https://doi.org/10.1007/s00345-023-04412-0
doi: 10.1007/s00345-023-04412-0
pubmed: 37209143
pmcid: 10352444
Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C et al (2019) Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 30(12):1914–1924. https://doi.org/10.1093/annonc/mdz414 . (PMID: 31613312)
doi: 10.1093/annonc/mdz414
pubmed: 31613312
Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H et al (2020) Sex-associated molecular differences for cancer immunotherapy. Nat Commun 11(1):1779. https://doi.org/10.1038/s41467-020-15679-x
doi: 10.1038/s41467-020-15679-x
pubmed: 32286310
pmcid: 7156379
Lu Y, Zhu Y, Ma W, Liu N, Dong X, Shi Q et al (2023) Estrogen associates with female predominance in Xp112 translocation renal cell carcinoma. Sci Rep 13:6141
doi: 10.1038/s41598-023-33363-0
pubmed: 37061606
pmcid: 10105720
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U et al (2023) Clinico-pathological features influencing the prognostic role of body mass index in patients with advanced renal cell carcinoma treated by immuno-oncology combinations (ARON-1). Clin Genitourin Cancer 21(5):e309–e319. https://doi.org/10.1016/j.clgc.2023.03.006
doi: 10.1016/j.clgc.2023.03.006
pubmed: 37062658
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S et al (2022) Concomitant use of statins, metformin, or proton pump inhibitors in patients with advanced renal cell carcinoma treated with first-line combination therapies. Target Oncol 17(5):571–581. https://doi.org/10.1007/s11523-022-00907-9 . (Epub 2022 Aug 10 PMID: 35947324)
doi: 10.1007/s11523-022-00907-9
pubmed: 35947324
Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G et al (2022) Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer 172:191–198. https://doi.org/10.1016/j.ejca.2022.04.035 . (Epub 2022 Jun 30 PMID: 35780525)
doi: 10.1016/j.ejca.2022.04.035
pubmed: 35780525
Tulchiner G, Pichler R, Ulmer H, Staudacher N, Lindner AK, Brunner A et al (2021) Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. Cancer Immunol Immunother 70(10):2805–2817. https://doi.org/10.1007/s00262-021-02882-y
doi: 10.1007/s00262-021-02882-y
pubmed: 33646368
pmcid: 8423679
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U et al (2023) Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncol 18(4):559–570. https://doi.org/10.1007/s11523-023-00978-2 . (Epub 2023 Jun 27 PMID: 37369815)
doi: 10.1007/s11523-023-00978-2
pubmed: 37369815
Porta C, Bamias A, Zakopoulou R, Myint ZW, Cavasin N, Iacovelli R et al (2023) Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. Minerva Urol Nephrol 75(4):460–470. https://doi.org/10.23736/S2724-6051.23.05369-7 . (PMID: 37530662)
doi: 10.23736/S2724-6051.23.05369-7
pubmed: 37530662
Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM et al (2009) Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 18(4):1174–1182. https://doi.org/10.1158/1055-9965.EPI-08-1118 . (Epub 2009 Mar 17 PMID: 19293308)
doi: 10.1158/1055-9965.EPI-08-1118
pubmed: 19293308
pmcid: 2793271
Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF (2011) Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev 20(8):1629–1637. https://doi.org/10.1158/1055-9965.EPI-11-0246 . (Epub 2011 Jul 12 PMID: 21750167)
doi: 10.1158/1055-9965.EPI-11-0246
pubmed: 21750167
pmcid: 3153584
Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84(3):223–243. https://doi.org/10.1006/clin.1997.4412 . (PMID: 9281381)
doi: 10.1006/clin.1997.4412
pubmed: 9281381
Griesbeck M, Scully E, Altfeld M (2016) Sex and gender differences in HIV-1 infection. Clin Sci 130(16):1435–1451. https://doi.org/10.1042/CS20160112 . (PMID: 27389589)
doi: 10.1042/CS20160112
Grigg C, Trufan S, Clark PE, Riggs SB, Zhu J, Justin T et al (2021) Survival trends of men and women with metastatic clear cell renal cell carcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.4566
doi: 10.1200/JCO.2021.39.15_suppl.4566
Hassler MR, Abufaraj M, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV et al (2020) Impact of patients’ gender on efficacy of immunotherapy in patients with metastatic kidney cancer: a systematic review and meta-analysis. Clin Genitourin Cancer 18(2):88-94.e2. https://doi.org/10.1016/j.clgc.2019.09.004 . (Epub 2019 Sep 27 PMID: 31668768)
doi: 10.1016/j.clgc.2019.09.004
pubmed: 31668768
Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A et al (2017) Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1–2 N0 M0 renal cell carcinoma. World J Urol 35(12):1899–1905. https://doi.org/10.1007/s00345-017-2082-9 . (Epub 2017 Aug 28 PMID: 28849260)
doi: 10.1007/s00345-017-2082-9
pubmed: 28849260
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN (2024) Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol. https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA359
doi: 10.1200/JCO.2024.42.4_suppl.LBA359
pubmed: 38701382
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M et al (2021) Cabozantinib in pretreated patients with metastatic renal cell carcinoma with sarcomatoid differentiation: a real-world study. Target Oncol 16(5):625–632. https://doi.org/10.1007/s11523-021-00828-z . (Epub 2021 Aug 2 PMID: 34338966)
doi: 10.1007/s11523-021-00828-z
pubmed: 34338966
Polanczyk MJ, Hopke C, Vandenbark AA, Offner H (2006) Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 84(2):370–378. https://doi.org/10.1002/jnr.20881 . (PMID: 16676326)
doi: 10.1002/jnr.20881
pubmed: 16676326
Ding J, Yeh CR, Sun Y, Lin C, Chou J, Ou Z, Chang C, Qi J, Yeh S (2018) Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. Oncogene 37(37):5037–5053. https://doi.org/10.1038/s41388-018-0175-6 . (Epub 2018 May 23 PMID: 29789714)
doi: 10.1038/s41388-018-0175-6
pubmed: 29789714
Ning K, Peng Y, Jiang Y, Li Z, Luo X, Lin L et al (2023) Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8+ T-cells highly infiltrated in males. Biol Sex Differ 14(1):58. https://doi.org/10.1186/s13293-023-00540-9
doi: 10.1186/s13293-023-00540-9
pubmed: 37715192
pmcid: 10503187
Ma J, Yao Y, Tian Y, Chen K, Liu B (2022) Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. Biol Sex Differ 13(1):58. https://doi.org/10.1186/s13293-022-00469-5 . (PMID: 36273184)
doi: 10.1186/s13293-022-00469-5
pubmed: 36273184
pmcid: 9587634
Ricketts CJ, Linehan WM (2015) Gender specific mutation incidence and survival associations in clear cell renal cell carcinoma (CCRCC). PLoS ONE 10(10):e0140257. https://doi.org/10.1371/journal.pone.0140257 . (PMID: 26484545)
doi: 10.1371/journal.pone.0140257
pubmed: 26484545
pmcid: 4618848
Kim YS, Unno T, Kim BY, Park MS (2020) Sex differences in gut microbiota. World J Mens Health 38(1):48–60. https://doi.org/10.5534/wjmh.190009 . (Epub 2019 Mar 25 PMID: 30929328)
doi: 10.5534/wjmh.190009
pubmed: 30929328
Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U et al (2013) Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339(6123):1084–1088. https://doi.org/10.1126/science.1233521
doi: 10.1126/science.1233521
pubmed: 23328391
Irelli A, Sirufo MM, D’Ugo C, Ginaldi L, De Martinis M (2020) Sex and gender influences on cancer immunotherapy response. Biomedicines 8(7):232. https://doi.org/10.3390/biomedicines8070232 . (PMID: 32708265)
doi: 10.3390/biomedicines8070232
pubmed: 32708265
pmcid: 7400663
Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC et al (2022) Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol 40(13):1474–1486. https://doi.org/10.1200/JCO.21.02377
doi: 10.1200/JCO.21.02377
pubmed: 35119908
pmcid: 9061143
Libert C, Dejager L, Pinheiro I (2010) The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 10(8):594–604
doi: 10.1038/nri2815
pubmed: 20651746
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P et al (2021) Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion. Clin Cancer Res 27(15):4311–4324. https://doi.org/10.1158/1078-0432.CCR-21-0136
doi: 10.1158/1078-0432.CCR-21-0136
pubmed: 34016641
pmcid: 7611463
Xu X, Li J, Zou J, Feng X, Zhang C, Zheng R et al (2019) Association of germline variants in natural killer cells with tumor immune microenvironment subtypes, tumor-infiltrating lymphocytes, immunotherapy response, clinical outcomes, and cancer risk. JAMA Netw Open 2(9):e199292. https://doi.org/10.1001/jamanetworkopen.2019.9292 . (Erratum.In:JAMANetwOpen.2020Apr1;3(4):e206708 PMID: 31483464)
doi: 10.1001/jamanetworkopen.2019.9292
pubmed: 31483464
pmcid: 6727785
Scelo G, Li P, Chanudet E, Muller DC (2018) Variability of sex disparities in cancer incidence over 30 years: the striking case of kidney cancer. Eur Urol Focus 4(4):586–590. https://doi.org/10.1016/j.euf.2017.01.006 . (Epub 2017 Jan 31 PMID: 28753845)
doi: 10.1016/j.euf.2017.01.006
pubmed: 28753845
Perera ND, Bellomo TR, Schmidt WM, Litt HK, Shyu M, Stavins MA et al (2023) Analysis of female participant representation in registered oncology clinical trials in the united states from 2008 to 2020. Oncologist 28(6):510–519. https://doi.org/10.1093/oncolo/oyad009
doi: 10.1093/oncolo/oyad009
pubmed: 36848266
pmcid: 10243778
Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
doi: 10.1001/jamanetworkopen.2019.2535
pubmed: 31050774
pmcid: 6503493
Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C et al (2019) Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 30(12):1914–1924. https://doi.org/10.1093/annonc/mdz414 . (PMID: 31613312)
doi: 10.1093/annonc/mdz414
pubmed: 31613312